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PAI-1, an important component of the hemostasis system, is a specific inhibitor of both urokinase type and
tissue type plasminogen activators. PAI-1 belongs to the serpin family. The interaction between
somatomedin-like domain of vitronectin and PAI-1 leads to stabilization of the latter. PAI-1 latency
transition is related to the conformational changes in the reactive central loop. The inhibitory mechanism of 
PAI-1 is in accordance with the classic scheme of serpin action. PAI-1 blocks the adhesion mediated by UPA 
and integrins, so this inhibitor plays an important role in adhesion process and angiogenesis. An altered
PAI-1level is associated with the development of cardiovascular diseases, kidney fibrosis, diabetis,
cancerogenesis. 
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PAI-1 belongs to the serpin family (serine proteinase
inhibitors) and is a natural specific inhibitor of both
tissue plasminogen activator (TPA) and urokinase one
(UPA). Among the components of hemostasis PAI-1
plays a very important role due to its unique structural
and functional peculiarities. In the last decade the
convinced proofs were obtained concerning the
participation of this protein not only in fibrinolysis but
also in cell adhesion modulation. The elevation of
PAI-1 level in plasma is observed at tumor growth and
under other pathological states in human organism. The 
PAI-1 deficiency in plasma can lead to bleeding while
the PAI-1 level elevation is related with the risk of
cardiovascular diseases such as myocardium
infarction, arteriosclerosis, deep vein thrombosis [1,2].
During kidney disease the level of PAI-1 in this tissue
is considerably increased which can lead to fibrotic
complications [3]. During adiposis the inhibitor
biosynthesis takes place in adipocytes immediately [4,
5]. PAI-1 may be of significance at chronic
inflammatory processes in lung tissue [6]. Some
authors, considering the role of PAI-1 in pathological
processes, noticed that high level of PAI-1 is
unfavorable index in cancer and cardiovascular
diseases [1,3-8]. 
Besides PAI-1 in human organism there are two
other plasminogen activator inhibitors known as PAI-2
and PAI-3 [9-11]. They differ from PAI-1 by their
molecular masses, content in plasma and are less
specific towards plasminogen activators (see table 1). It 
was established, that PAI-3 has a specific function as
an inhibitor of activated protein C which is one of the
main components of anticoagulant system. A
biological function of PAI-2 has not been defined yet.
255
ISSN 1993-6842. Biopolymers and cell. 2010. vol. 26. N 4. Translated from Ukrainian
 Institute of Molecular Biology  and Genetics NAS of Ukraine, 2010 
Among these proteins PAI-1 is the most interesting,
because this inhibitor has structural peculiarities,
which help it to interact with the components of
extracellular matrix and therefore its functional role is
more complicated [12, 13].
The average concentration of PAI-1 in human
plasma is 24 ng/ml, but it can fluctuate from 6 to 85
ng/ml. The PAI-1 concentration is 2-3 times more in
arterial blood than in venous one [14, 15]. Besides, the
concentration of this inhibitor is changing during the
day: it is higher before noon than in the afternoon [11].
According to a modern version, the pool of PAI-1 is
formed from several sources: platelets, hepatocytes,
endothelial cells, macrophages, and adipocytes [16].
Platelets contain approximately 90% of PAI-1. 
Structural peculiarities of PAI-1.  The gene of
human PAI-1 is localized on chromosome 7 in the
region q 21.3-q 22 [17]. It contains 9 exons and 8
introns. Higher primates have two different transcripts
of PAI-1 m-RNA: 2.6 and 3.6 kb. However, the
translation products are the proteins of the same size
[18]. The transcription and translation of platelet PAI-1 
occur in megakariocytes. However, megakaryocytes
contain a considerable amount of PAI-1 m-RNA,
which biosynthesis goes on at the platelet stage [19].
The PAI-1 gene transcription is regulated by a large
number of hormones, cytokines, and growth factors
[16, 20, 21]. The induction of PAI-1 expression by
glucocorticoid hormones is of special interest, as PAI-1 
was discovered as a dexamethasone-induced
fibrinolytic inhibitor [22].
PAI-1 is synthesized as a precursor containing 402
amino acid residues (Fig. 1). During protein globule
formation the signal peptide of 21 or 23 residues is
cleaved from the molecule. So, the mature protein
contains 379 or 381 amino acid residues [23, 24].
PAI-1 has 3 potential glycosylation sites at Asn 232,
Asn288, and Asn 352 [25]. The glycosylation PAI-1
depends on its origin in human organism.
It was shown that PAI-1, purified from plasma or
platelets of healthy donors, had no glycans, meanwhile
PAI-1 from endothelial cells or adipose tissue was
glycosylated. It led to the conclusion, that the main
source of PAI-1in plasma of healthy people could be
platelets but not endothelial cells [26]. The recent
investigations have shown the importance of
glycosylation for the functional activity of PAI-1. The
glycosylated form of PAI-1 was found to possess a
higher inhibitor activity [27]. 
Interaction of PAI-1 with vitronectin. The
binding of vitronectin is very important for PAI-1
functioning [13, 28]. Vitronectin is found in plasma in 
a concentration of 2-4µM, mainly in a monomeric
conformation, however, it has multimeric form in
extracellular matrix [29]. PAI-1 is present in
α-granules of platelets as a complex with vitronectin
[30-32]. Using the methods of electron microscopy
[33] and FITC-labeled proteins in flow cytometry [34] 
256
ZHERNOSSEKOV D. D., ZOLOTAREVA E. N., KONDRATUK A. S. 
Name Concentration in human plasma Molecular mass, êDa
The constant inhibition (Ì-1ñ-1)  toward 
UPA TPA
PAI-1 In average 24 ng/ml 52 106 107
PAI-2 Negligible under normal state.At pregnancy 100 – 300 ng/ml 60 9⋅10
5 2⋅105
PAI-3 2–5 µg/ml 57 8⋅103 103
Characteristics of PAI proteins
EPGTVLFMGQVM FLFVVRHNPTAPEEIIMDRPSTAVIVSAR*MI
400390380370
VNESGTVASSAQALQKVKIESLSDQEPLHVMFRQFQADFTKPLENLGMTDFSLETEVDLR
360350340330320310
RLPRLLVLPKLISHWKGNMTSALTNILSAQAAPYEKEVPLYHGDTLSMFIGHYYDILELP
300290280270260250
FNYTEFTTPDSVPMMAQTNKLFHKSDGSTVPFPDSSTHRRALYFNGQWKTDQLTRLVLVN
240230220210200190
ISNLLGKGAVDWVKTHTKGMEVERARFIINRSTVKQVDFSGFMPHFFRLFFVQRDLKLVQ
180170160150140130
KDEISTTDAILYKELMGPWNDKGMAPALRHIQAAMGFKIDLTTGGETQQQGVASVLAMLQ
120110100908070
KDRNVVFSPYRVFQQVAQASVAHLASDFGVGSAVHHPPSYVLGLALVFGEMQMSPALTCL
605040302010
Fig. 1. Primary structure of human PAI-1 (All numbers of amino
acid residues correspond to the protein premature form).
N-glycosylated Asn [25]; MQMSPALTCLVLGLALVFGEGSA or
MQMSPALTCLVLGLALVFGEG is a signal peptide [23, 24];
FRLFFRLFR and EVERARFIINDWVKTHTK are sites of
vitronectin binding [35, 36]; R*M is a peptide bond, which is
cleaved by TPA or UPA; PEEIIMDR is a site of TPA or UPA
binding. 
it was shown that after platelets activation and
releasing from α-granules the above-mentioned
complex stays on the surface of activated platelets.
The sites of vitronectin binding to PAI-1 were
determined [35, 36] (see Fig.1). The method of
site-directed mutagenesis showed that the most
important residues in PAI-1 structure, which provide
interaction with vitronectin, were Phe 132, Met 133,
Leu 139 and Gly 146 [37].
On the other hand, the somatomedin-like domain
(SMB) of vitronectin, containing 44 amino acid
residues, is in charge of PAI-1 binding [34]. It is
followed by the RGD sequence, which is known as an
integrin-binding site. It was shown that vitronectin can
bind C-terminal part of vimentin, which is exposed on
the membrane of activated platelets [34].
During the experiments with immobilized proteins it 
was established that Kd value for binding immobilized
vitronectin to PAI-1 was 1.9×10-7 , however, if PAI-1
was immobilized , its Kd value for vitronectin binding
was 5. 5×10-8 . So, it was made a conclusion, that in
vitronectin molecule there are at least two sites of PAI-1
binding, and one of these sites, which has higher affinity, 
becomes unapproachable after immobilization [38, 39].
The site of PAI-1 binding on the vitronectin molecule is
different from integrin-binding site RGD. However,
PAI-1 binding in the region of SMB domain can inhibit
cell adhesion induced by integrins, possibly due to
physical barrier [40, 41].
PAI-1 latency transition. PAI-1 can be found in
active S (stressed) or latent R (relaxed) state [42]. It is
known, that this protein is synthesized in an active
configuration but spontaneously can convert to
thermodynamically more stable latent form [43].
Reported half-life of the active PAI-1 is approximately
1-2 hours at 37° C and pH 7.4. However, this time can
be decreased under conditions of low temperature and
pH [44, 45]. In plasma the active PAI-1 is stabilized by
its binding with vitronectin. The Kd value for binding
of vitronectin to the active PAI-1 is 80 nM, while the
latent PAI-1 binds with at least 200-fold lower affinity
[46]. PAI-1 can be reactivated in vitro by treatment
with denaturants such as SDS, guanidine HCl, and urea
[43]. It has been suggested that negatively charged
phospholipids exposed on the surface of activated
platelets could reactivate PAI-1 [47].
Studying the latency transition of PAI-1 the
researchers showed that this process was related with
the changes in tertiary structure. This transition is one of 
the largest structural rearrangements known for a folded
protein without a concomitant change in covalent
structure. It was shown that some mutations could
decrease the rate of latency transition [48]. So, the
methods of site-directed mutagenesis are successfully
used to study PAI-1 conformation transition.
To consider the mechanism of PAI-1
stressed-to-relaxed transition we should pay attention to
the peculiarities of secondary and tertiary structures of
this protein. There are 9 parts of alpha-helical structures
marked as hA-hI and the strands of beta-sheet structure
form beta-sheets A, B, and C. As it is shown at Fig. 2
beta-sheet A contains 6 strands (s1A-s6A) and
beta-sheet C has 4 strands (s1C-s4C). There is a flexible
site between beta sheets A and C. It contains 17 amino
acid residues that is a site of recognition by serine
proteases, so called central reactive loop (CRL). In the
structure of CRL there is a special site P1-P’1, which is
attacked by proteases. In case of PAI-1 this is a peptide
bond Arg 369-Met 370 [49].
During S-R transition the N-terminal part of CRL
inserts into beta-sheet A as s4A (see Fig.2, black
arrow), and its C-terminal extension, forming s1C in
the active conformer, stretched out along the surface of
the molecule. As the P1-P1 ' is not cleaved during
latency transition, the intact CRL must be stretched out
and completely extracted from beta-sheet A and pass a
narrow gate region between s3C and s4C. As a result
s4A can be completed [50]. The rate of S-R for PAI-1
was suggested to be limited by the rate of CRL passage
through the above mentioned gate region. This
suggestion is in concordance with the data, obtained
when basic amino acid residues in the loop s3C/s4C
were substituted with acidic ones. Such substitution
leads to the acceleration of latency transition [51].
Amino acid residues in the s1C region are also very
important for the PAI-1transition into latent state. It
was shown that mutations, which led to weakness of
interactions in this region, facilitated the
conformational transition to the latent state and
affected the overall structural stability of PAI-1 [52].
The presence of halide ions makes essential
influence on latency transition. Crystallografic
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analysis of a stable mutant form of active PAI-1
identified an anion-binding site between the central
beta-sheet, where CRL was inserted, and the small
surface domain. The anion insertion stabilized the active
form of PAI-1. The stabilization induced by halide-anion
was decreased in a row: F->Cl->Br->>I- [53].
The binding of vitronectin to PAI-1 also influences
the S-R transition. Half-life of the PAI-1 active form
significantly increases in the presence of vitronectin
[13, 28]. Some authors suggested that vitronectin
induced conformational changes in CRL [54, 55].
Later, studying a three-dimensional structure of
PAI-1-somatomedin B complex, the researchers made
a conclusion that vitronectin sterically impedes the
transition of s2A and s3A towards hE helical structure.
So, the opening of beta-sheet A, which is important for
CRL insertion, can be delayed. It is known that CRL
insertion as s4A strand, which takes place during the
PAI-1 latency transition, is accompanied with the
transition of s1A, s2A, s3A, hF and the linking region
binding hF and s3A. There are also some changes in the 
flexible linking region, which is close to the helical
structures hE and hD. However, the data, obtained with 
the substitution of Lys 346 in s5A strand, suggested
more complicated mechanism of vitronectin
participation. It was shown that changing this lysine
residue with alanine in PAI-1 structure in the absence
of vitronectin delayed latency transition meanwhile in
the presence of vitronectin such substitution led to the
acceleration of this process [57]. It is obvious that
vitronectin not only makes sterical effect but also leads
to the conformational changes in PAI-1 structure. It is
in concordance with the data of Sui G. S. et al [58].
They showed that significant acceleration of latency
transition induced by point mutation in s1A and hF in
PAI-1 protein was not observed in the presence of
vitronectin.
There is another proposed mechanism concerning
the PAI-1 transition into latent state and the role of
vitronectin during this process [59]. According to the
proposed model, there are some conformation states of
PAI-1 (I-IV), which are determined by reciprocal
location of s3A and s5A in A-sheet. State I: s3A and
s5A are situated close to each other along their whole
length. In this state CRL can not be inserted into sheet
A. State II: s3A and s5A widen out near CRL, so the
loop can be inserted into sheet A for a short distance.
State III: CRL is inserted into sheet A till the P11
residue. State IV (latent state): CRL is completely
inserted into sheet A. This state is practically
irreversible under physiological conditions. The
authors of this work suppose that in the presence of
vitronectin the equilibrium between states II and III is
shifted towards state II. As a result the latency
transition of PAI-1 can be delayed.
Inhibitory mechanism of PAI-1. The inhibitory
mechansm of PAI-1 was described in the literature,
however, some details of this mechanism were not
clarified [60]. Using modern biophysical and
biochemical methods e.g. X-ray analysis, the main
steps of the inhibition have been studied. The
postulated mechanism suggests the following: 1)
formation of a reversible Michaelis complex, where
P1-P1' bond in CRL docks into the active site of serine
protease; 2) splitting peptide bond P1-P1' and formation
of an acyl-enzyme intermediate, in which the serine in
active site of the protease is attached to the carbonyl
group of Arg residue, which is located at P1 of the
serpin molecule; 3) insertion of the N-terminal side of
CRL into beta-sheet A, due to that the dragging of the
protease to the other pole of serpin takes place; 4)
deformation of the protease active site, preventing
completion of the catalytic cycle [9, 61, 62]. UPA and
TPA attack peptide bond Arg 369-Met 370 in PAI-1
molecule [63-66]. The substitution of these residues by
the method of site-directed mutagenesis showed the
importance of this peptide bond for the active centre of
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Fig. 2. Schematic beta-sheets A and C in serpin structure [49].
TPA molecule. After splitting this bond, Arg 369 of
PAI-1 and serine of the protease active centre form the
ester bond. The existence of such bond was proved by
direct methods of the protein chemistry [67]. In PAI-1
molecule amino acid residues Glu 373 and Glu 374 are
very important for this reaction. They are
complementary to the certain sites in 37-th loop of
UPA and TPA, Arg 179-Arg 182 and Lys 296-Arg 304, 
correspondingly [68, 69]. The second order rate
constants for the inhibition reaction are 107 M-1c-1 and
106 M-1c-1 for TPA and UPA, respectively [70].
Depending on the conditions, some stages of PAI-1 
inhibition reaction are probably reversible. So, the
covalent complex PAI-1-TPA (M.m. 110kDa), which
is rather stable under physiological conditions, can be
accomplished with NH4OH [71] or SDS [72]. In
circulating plasma PAI-1 can be present in three states:
active state in a complex with vitronectin, inactive state 
as a complex PAI-1-vitronectin-TPA and free state
[73-75]. The last one is also called split form.
According to the proposed mechanism there are two
alternative pathways of the protease-serpin reaction.
The covalent acyl-enzyme intermediate can go either
of two paths: 1) leading to the stable serpin-protease
complex formation or 2) disintegration of intermediate
complex with the formation of reactive centre-cleaved
serpin and active protease. The equilibrium of these
processes depends on temperature, ionic strength,
detergents [76-78]. 
Under physiological conditions the PAI-1-protease 
complex can probably circulate in plasma till the
moment when it is bound to the low density lipoprotein
receptor 1B (LRP1B) of hepatocytes. After binding
with this receptor, the complex PAI-1-TPA enters into
the cell by phagocytosis and degrades under action of
intracellular proteases [79].
Being the inhibitor of serine proteases, PAI-1 is
able to inhibit not only TPA and UPA, but also the
activated protein C and thrombin, however, for these
proteins there are specific inhibitors in plasma (protein
C inhibitor and antithrombin III). It is thought that the
activated protein C binding with PAI-1shows its
pro-fibrinolytic activity. The second rate constant for
the activated protein C inhibition by PAI-1 is 103 M-1
c-1[80,81] In the presence of vitronectin this value was
1.8 ×105 M-1 c-1 [82]. Noteworthy  that under similar
conditions the rate of the reaction between PAI-1 and
TPA was 100 times higher, so protein C can affect the
TPA activation only being in concentration excess [70,
82]. The activated protein C forms stable complexes
with PAI-1 which can be eliminated from plasma by
endothelial cells [43].
PAI-1 as a modulator of cell adhesion in tumor
cells. Plasminogen, PAI-1, urokinase, and its specific
receptor UPAR take part in the mitogenic, chemotactic, 
adhesive and migratory processes in cells. These
components of fibrinolytic system play an important
role in the neovascularization and tumor development
[83]. It was shown that tumor tissues express urokinase
and UPAR because these molecules provide tumor
cells with proteolytic activity, which is a precondition
for invasion [84, 85]. 
UPAR consists of three structural domains: D1,
D2 and D3. The N-terminal domain, which is called
D1, has a sequence responsible for urokinase binding,
whereas D2 is needed for interaction with vitronectin
[85]. In vitronectin molecule the SMB domain
contains site for UPAR binding [85]. Urokinase
binding with its specific receptor increases the UPAR
affinity towards vitronectin and leads to the formation 
of stable complex between UPAR and some integrins
(e.g. β1 and β3 integrins) [86], and induces activation
of signal molecules, which are essential for the cell
migration [84, 85].
It was found that the increase in urokinase level was 
accompanied by the elevation of PAI-1 concentration
in plasma. That effect was observed for many types of
tumor. Some authors showed that PAI-1 prevented
cellular adhesion mediated by integrins and UPAR [84, 
85, 87]. The adhesion inhibition by PAI-1 was
observed for U937 cells (adhesion is provided by
UPAR binding with vitronectin), MCF7 cells (make
adhesive contact with vitronectin through integrins),
HT1080 and HeLa (they use both adhesive receptors)
[85]. The binding sites for PAI-1, UPAR and integrins
are closely situated at the N-terminal part of vitronectin 
molecule. So PAI-1 can be considered as a possible
competitor inhibitor in the interaction of UPAR or
integrins with vitronectin [36, 85]. It was shown that
the inhibition of adhesive process depends on the
binding of the inhibitor to the SMB domain of
vitronectin [88]. As a result PAI-1 is able to be in the
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way of adhesive contacts, which are mediated by
integrins, thus promoting cell migration (see. Fig.3).
Besides, the components of fibrinolytic system take
part in the neovascularization process of tumor cells.
Urokinase and plasmin can contribute to angiogenesis
by degrading the components of extracellular matrix
and taking part into migration of endothelial cells. At
the same time proteolysis induced by plasmin is
controlled by physiological inhibitors such as PAI-1 to
stabilize matrix and to group endotheliocytes during
the vessel formation [85]. Angiogenic effect of PAI-1
depends on its concentration, tumor type and stage.
PAI-1 deficiency has no effect on sarcoma
development, melanoma metastasis, primary tumor
growth and tumor extension in the model of
adenocarcinoma of mammary glands [2]. PAI-1
deficiency prevents tumor invasion and
vascularization. However, invasion and angiogenesis
are restored if PAI-1deficiency compensated and
expression renewed. So, PAI-1 can contribute to the
invasion and vascularization of tumor cells [88].
Recent researches have shown that a role of PAI-1 in
cell migration is ambiguous and depends on its
interaction with vitronectin. If PAI-1 forms a complex
with vitronectin, the signaling and cell migration are
suppressed [89]. These data are in accordance with the
fact that PAI-1 prevents cell migration, which is
induced by UPAR [90]. On the other hand, as it was
mentioned above, PAI-1 competes for vitronectin
binding site on the cellular surface, impedes cellular
adhesion, which is mediated by integrins, and promotes 
cell migration. Apparently, the cell migration process
depends not only on PAI-1 concentration but also on
the type of its active form (vitronectin-bound or
non-bound).
Perspectives of PAI-1 investigations. The
inhibitors of serine proteases are very attractive for
investigators because of their wide spread occurrence
in nature. They are found in all living systems except
bacteria [9]. In general, serpins control proteolytic
degradation, but, as it was shown in case of PAI-1, their 
biological functions can be more complicated. One of
the promising approaches to the serpin usage is the
synthesis of compounds which possess the same
efficiency as the natural inhibitors, but have their CRLs 
in constantly active state. These compounds could be
used to inactivate the proteases of pathogenic
microorganisms.
If the amount or activity of PAI-1 could be
regulated we would be able to control the cellular
adhesive properties and mobility which has a great
importance for therapy [83]. Some authors consider
PAI-1 as a potential target in tumor diseases [54, 55],
therefore, the screening of agents inactivating PAI-1 is
an important part of the modern investigations. Some
peptides or monoclonal antibodies may be possible
candidates. These agents of directed action have to be
tested first on animal models, and in future they could
be a base for creating medical preparations.
Ä. Ä. Æåð íî ñå êîâ, Ý. Í. Çî ëî òà ðå âà, À. Ñ. Êîí äðà òþê
Ñòðóê òóð íî-ôóíê öè î íàëü íûå îñî áåí íîñ òè èí ãè áè òî ðà àê òè âà -
òî ðà ïëàç ìè íî ãå íà ÏÀÈ-1
Ðå çþ ìå
ÏÀÈ-1,âàæ íûé êîì ïî íåíò ñèñ òå ìû ãå ìîñ òà çà, ÿâ ëÿ åò ñÿ ñïå -
öè ôè ÷åñ êèì èí ãè áè òî ðîì àê òè âà òî ðîâ ïëàç ìè íî ãå íà òêà íå -
âî ãî (ÒÏA) è óðî êè íàç íî ãî (ÓÏÀ) òè ïîâ. ÏÀÈ-1 îò íî ñèò ñÿ ê
ñå ìå éñòâó ñåð ïè íîâ. Âçà è ìî äå éñòâèå ñ ñî ìà òî ìå äè íî ïî äîá -
íûì äî ìå íîì âèò ðî íåê òè íà ñòà áè ëè çè ðó åò àê- òèâ íóþ ôîð ìó 
èí ãè áè òî ðà. Ïå ðå õîä ÏÀÈ-1 â ëà òåí òíîå ñî ñòî ÿ íèå ñî ïðÿ æåí 
ñ êîí ôîð ìà öè îí íû ìè èç ìå íå íè ÿ ìè â îá ëàñ òè ïåò ëè ðå àê òèâ -
íî ãî öåí òðà. Ìå õà íèçì èí ãè áè òîð íî ãî äå éñòâèÿ ÏÀÈ-1 ñî îò -
âå òñòâó åò êëàñ ñè ÷åñ êîé ñõå ìå èí ãè áè ðî âà íèÿ ñåð ïè íà ìè.
ÏÀÈ-1 áëî êè ðó åò àä ãå çèþ, îïîñ ðå äî âàí íóþ ðå öåï òî ðîì ÓÏÀ è 
èí òåã ðè íà ìè, âû ïîë íÿÿ ïðè ýòîì âàæ íóþ ðîëü â àä ãå çèâ íûõ
ïðî öåñ ñàõ è àí ãè î ãå íå çå. Èçìå íå íèÿ óðîâ íÿ ÏÀÈ-1 ðàñ ñìàò ðè -
âà þò êàê âàæ íûé ïðî ãíîñ òè ÷åñ êèé ïðè çíàê ïðè çà áî ëå âà íè ÿõ
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Fig. 3. Schematic possible influence of PAI-1 on cell adhesion
process. UPA-urokinase, UPAR-urokinase receptor,
Vn-vitronectin.
ñåð äå÷ íî-ñî ñó äèñ òîé ñèñ òå ìû (èí ôàðêò ìè î êàð äà, èí ñóëüò),
ôèá ðî çå ïî ÷åê, äè à áå òå, êàí öå ðî ãå íå çå.
Êëþ ÷å âûå ñëî âà: ÏÀÈ-1, ôèá ðè íî ëèç, ìèã ðà öèÿ êëå òîê. 
Ä. Ä. Æåð íîñºêîâ, Å. Ì. Çî ëî òàðü î âà, A. Ñ. Êîí äðà òþê
Ñòðóê òóð íî-ôóíêö³îíàëüí³ îñîá ëè âîñò³ ³íã³á³òîðà àê òè âà òî ðà
ïëàçì³íî ãå íó ÏÀ²-1
Ðå çþ ìå
ÏÀ²-1, âàæ ëè âèé êîì ïî íåíò ñèñ òå ìè ãå ìîñ òà çó, º ñïå öèô³÷-
íèì ³íã³á³òî ðîì àê òè âà òîð³â ïëàçì³íî ãå íó òêà íèí íî ãî (ÒÏÀ)
òà óðîê³íà çíî ãî òèï³â. ÏÀ²-1 íà ëå æèòü äî ñåðï³íî âî¿ ðî äè íè.
Âçàºìîä³ÿ ç ñî ìà òî ïîä³áíèì äî ìå íîì â³òðî íåê òè íó ñòàá³ë³-
çóº àê òèâ íó ôîð ìó ³íã³á³òîðà. Ïå ðåõ³ä ÏÀ²-1 äî ëà òåíòíîãî
ñòà íó ïî â’ÿ çàíèé ç êîí ôîð ìàö³éíè ìè çì³íàìè ó ä³ëÿíö³ ïåòë³
ðå àê òèâ íî ãî öåíòðà. Ìå õàí³çì ³íã³á³òîð íî¿ ä³¿ ÏÀ²-1 â³äïî-
â³äàº êëà ñè÷í³é ñõåì³ ñåðï³íî âî ãî ³íã³áó âàí íÿ. ÏÀ²-1 áëî êóº àä -
ãåç³þ îïî ñå ðåä êî âà íó ðå öåï òî ðîì ÓÏÀ òà ³íòåã ðè íà ìè, âè êî -
íó þ ÷è ïðè öüî ìó âàæ ëè âó ðîëü â àä ãå çèâ íèõ ïðî öåñ ñàõ òà
àíã³îãå íåç³. Çì³íè ð³âíÿ ÏÀ²-1 ðîç ãëÿ äà þòü ÿê ³ñòîò íó ïðî ãíî-
ñòè÷ íó îçíà êó ïðè çà õâî ðþ âàí íÿõ ñåð öå âî-ñó äèí íî¿ ñèñ òå ìè,
ô³áðîç³ íè ðîê, ä³àáåò³, êàí öå ðî ãå íåç³.
Êëþ ÷îâ³ ñëî âà: ÏÀ²-1, ô³áðè íîë³ç, ì³ãðàö³ÿ êë³òèí.
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